Saturday, 23 October 2021 07:57 GMT

Sepsis Market Analysis: Insights into Epidemiology Segmentation, Treatment Landscape, Emerging Therapies, and Key Companies

(MENAFN- GetNews) The anticipated launch of emerging therapies such as Nangibotide, Recomodulin, and others are expected to have a significant impact on the growth of the Sepsis market size during the study period 2018-30 in the 7MM.

DelveInsight's Sepsis market report offers comprehensive coverage of the current treatment practices, pipeline therapies, and market share of the individual drug, current and forecasted Sepsis market size from 2018 to 2030 in the 7MM.

Some of the Crucial Highlights from the Sepsis Market Report  

  • As per DelveInsight estimates, the total Sepsis incidence was over 3 million in the 7MM in 2020, with the US accounting for the maximum Sepsis incidence.

  • Among the EU5 countries, Germany had the highest Sepsis incident cases while France accounted for the least Sepsis incident cases in 2020.

  • According to DelveInsight Sepsis epidemiology analysis, males are more affected as compared to females.

  • Leading players such as Shionogi, Inotrem, Asahi Kasei Pharma  Corp., Adrenomed, AM-Pharma, Revimmune , among others, are diligently working to improve the Sepsis treatment landscape.

  • Key Sepsis therapies in the pipeline include Fetroja/Fetcroja, Nangibotide, Recomodulin, Adrecizumab, Endogenous enzyme alkaline phosphatase, CYT107, and others.

  • CYT107 (Revimmune) could be a game-changer in treating sepsis patients, as it restores adaptive immunity.

  • The Sepsis market size was found to be USD 2,458 million in the 7MM in 2020. 

For further information on the disease, request for the sample @ Sepsis Treatment Guidelines

Sepsis Overview

Sepsis is a life-threatening organ failure induced by a faulty infection response. Sepsis is a clinical manifestation of infections that can be acquired in both the community and healthcare institutions. Sepsis can develop in anyone who has had an infection, a traumatic injury, or a serious non-communicable disease.

Sepsis Epidemiology Segmentation

The Sepsis report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

  • Sepsis Total Incident Cases

  • Sepsis Gender-Specific Incident Cases

  • Sepsis Severity-Specific Incident Cases

  • Sepsis Origin-Specific Incident Cases

Sepsis Therapeutics Market

The main option for Sepsis treatment is antibiotics, vasoactive medications, insulin, and painkillers. In severe Sepsis cases, extracorporeal therapies are also used. The most commonly used antibiotics for Sepsis treatment include ceftriaxone (off-label), meropenem (Merrem), ceftazidime  (Fortaz), cefotaxime (Claforan), cefepime (Maxipime), piperacillin and tazobactam (Zosyn),  ampicillin and sulbactam (Unasyn), imipenem/cilastatin (Primaxin), levofloxacin (Levaquin), and clindamycin (Cleocin). In addition, Oritavancin, dalbavancin, and tedizolid are among the FDA- approved antibiotics for Sepsis.

Apart from these, there are some marketed Sepsis therapies also such as GIAPREZA (angiotensin II), Vasostrict  (vasopressin), Empressin (Argipressin), and Recomodulin (ART-123).

Sepsis Market Outlook

The Sepsis market is expected to witness the launch of upcoming therapies by key pharmaceutical companies, including Shionogi, Inotrem, Asahi Kasei Pharma  Corp., Adrenomed, and several others. 

Get a detailed analysis of the market @ Sepsis Market Size

Sepsis Pipeline Therapies and Key Companies  

  • Fetroja/Fetcroja: Shionogi

  • Nangibotide: Inotrem

  • Recomodulin: Asahi Kasei Pharma  Corp.

  • Adrecizumab: Adrenomed

  • Endogenous enzyme alkaline phosphatase: AM-Pharma

  • CYT107: Revimmune

Sepsis Market Drivers

  • Rising Sepsis Incidence

  • Innovations in R & D strategies

  • Increasing awareness

  • Expected approval of pipeline drugs  in the forecasted period

  • Understanding of Sepsis pathophysiology

Sepsis Market Barriers

  • Lack of a gold standard test causes a delay in diagnosis.

  • The disease burden associated  with the high cost of  treatment

  • Limitations related to defining Sepsis

  • Trial Failures and Drug  withdrawal from the market

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)

Study Period: 2018-30

Sepsis Key Companies: Shionogi, Inotrem, Asahi Kasei Pharma  Corp., Adrenomed, AM-Pharma, Revimmune, among others.

Sepsis Key Pipeline Therapies: Fetroja/Fetcroja, Nangibotide, Recomodulin, Adrecizumab, Endogenous enzyme alkaline phosphatase, CYT107, and others.

Sepsis Segmentation: By Geography, By Sepsis therapies

Analysis: Comparative and conjoint analysis of Sepsis emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL's Views

Analyst's Views

Table of Contents


Key Insights


Report Introduction


Sepsis Market Overview at a Glance


Executive Summary of Sepsis


Sepsis Disease Background and Overview


Sepsis Epidemiology and Patient Population


Patient Journey


Organizations contributing towards Sepsis


Sepsis Marketed Therapies


Sepsis Emerging Therapies


Sepsis: Seven Major Market Analysis


Sepsis Seven Major Market Outlook


KOL Views


Sepsis Market Drivers


Sepsis Market Barriers


SWOT Analysis


Sepsis Unmet Needs


Sepsis Reimbursement and Market Access




DelveInsight Capabilities




About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Septic Shock Market

Get a comprehensive analysis of Septic Shock pipeline therapies and key companies such as Adrenomed AG, Vivacelle Bio, Inotrem, Atox Bio, AM-Pharma, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.